Welcome to our dedicated page for Rezolute news (Ticker: RZLT), a resource for investors and traders seeking the latest updates and insights on Rezolute stock.
Rezolute, Inc. develops therapies for rare and metabolic diseases, with recent company updates centered on hypoglycemia caused by hyperinsulinism. Its principal news themes include ersodetug, the Phase 3 sunRIZE study in congenital hyperinsulinism, the Phase 3 upLIFT study in tumor hyperinsulinism, and clinical evidence from continuous glucose monitoring, biomarker analyses and expanded access experience.
Rezolute news also covers FDA interactions, presentations at pediatric endocrinology and life sciences meetings, quarterly financial results, business updates and investor conference participation. The company’s updates generally connect clinical-program progress with regulatory engagement, cash resources and development priorities for its hyperinsulinism pipeline.
Rezolute (NASDAQ:RZLT), a late-stage rare disease company, has appointed Sunil Karnawat as Chief Commercial Officer effective August 18, 2025. Karnawat brings over 25 years of experience in global commercialization of biopharmaceuticals and medical devices, including successful launches of four ultra-rare disease products at Ultragenyx.
The appointment comes as Rezolute advances ersodetug through Phase 3 studies for both congenital and tumor hyperinsulinism. As part of his compensation package, Karnawat received an inducement stock option grant of 275,000 shares at $6.55 per share, with a four-year vesting schedule.
Rezolute (NASDAQ:RZLT), a late-stage rare disease company specializing in hypoglycemia treatment caused by hyperinsulinism, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025.
The company's management team will be available for one-on-one meetings with investors during the conference. Interested investors should coordinate with their BTIG representatives to schedule meetings.
Rezolute (NASDAQ:RZLT), a late-stage rare disease company, will present baseline data from its fully enrolled Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism at ENDO 2025. The presentation, scheduled for July 14, 2025, will focus on patient demographics and characteristics from the trial.
The company's Chief Medical Officer highlighted that the presentation will provide insights into the study population and its comparability to the Phase 2 RIZE study. With enrollment complete, topline data is expected in December 2025, marking progress toward a potential new treatment option for patients with limited alternatives.
The company plans to initiate a registrational study for tumor HI patients in mid-2025, with topline results expected in H2 2026. Rezolute will engage with the FDA to discuss the registrational trial and requirements for a BLA filing, aiming to expand ersodetug's indication beyond congenital HI.
The BTD status acknowledges ersodetug's potential to offer substantial improvement over existing treatments for this serious condition, where current standard care often fails to manage persistent hypoglycemia effectively.
Rezolute (NASDAQ: RZLT), a late-stage rare disease company specializing in treatments for hypoglycemia caused by hyperinsulinism, has announced its participation in four upcoming investor conferences in May and June 2025. The company's management will attend:
- The Citizens JMP Life Sciences Conference (May 7-8)
- H.C. Wainwright BioConnect Investor Conference (May 20)
- Craig-Hallum Institutional Investor Conference (May 28)
- Jefferies Global Healthcare Conference (June 3-5)
Management will be available for one-on-one meetings with investors during these conferences. Interested investors should contact their respective conference representatives to schedule meetings.
Rezolute (NASDAQ: RZLT) has successfully closed its previously announced underwritten offering, raising approximately $96.9 million in net proceeds. The offering included 24,940,769 shares of common stock at $3.25 per share, including 4,153,846 shares from the underwriters' option, and pre-funded warrants for 6,905,385 shares at $3.2490 per warrant.
The offering attracted notable investors including Federated Hermes Kaufmann Funds, Blackstone Multi-Asset Investing, and Great Point Partners. Additionally, existing investors have committed to purchase up to $4.2 million in shares through a separate private placement expected to close around May 7, 2025.
Guggenheim Securities served as the sole book-running manager, with BTIG, H.C. Wainwright & Co., and Jones as lead managers. The company plans to use the proceeds for research and development, general corporate expenses, and working capital needs.
Rezolute (NASDAQ: RZLT) has announced the pricing of an underwritten offering of common stock and pre-funded warrants, expected to raise approximately $90 million in gross proceeds. The offering includes 20,786,923 shares of common stock priced at $3.25 per share and pre-funded warrants for up to 6,905,385 shares at $3.2490 per warrant.
The offering features participation from notable investors including Federated Hermes Kaufmann Funds, Blackstone Multi-Asset Investing, and Great Point Partners. Guggenheim Securities is serving as the sole book-running manager. The closing is expected around April 24, 2025. The company plans to use the proceeds for research and development, general corporate expenses, and working capital needs.
Rezolute (NASDAQ: RZLT) received a positive recommendation from the Independent Data Monitoring Committee (DMC) for its Phase 3 sunRIZE study of ersodetug in Congenital Hyperinsulinism (HI). The DMC advised continuing the trial as planned without increasing the sample size.
The interim analysis was conducted after approximately half of enrolled patients completed primary assessments, focusing on hypoglycemia events as the primary endpoint. The company remains on track to complete enrollment in May 2025, with topline data expected in December 2025.
U.S. clinical sites are now active and enrolling patients as part of the global study. The company remains blinded to the partial study data and statistical outputs from the DMC. The recommendation aligns with previous Phase 2 RIZE study outcomes, real-world observations from their Expanded Access Program, and pharmacokinetic data from the sunRIZE study's open-label arm.